Clinical Briefs in Primary Care Supplement
CME Objectives
Upon completion of this activity, participants should be able to:
discuss the most recent information regarding diagnosis and treatment of various types of cancer;
describe current prevalence/surveillance data and long-term follow-up results of chemotherapy/radiation regimens; and
describe new advances in the field of oncology.
CME Questions
10. Which of the following cancer-patient groups are likely to benefit most from a pre-treatment assessment of "frailty"?
a. Patients 70-80 years old with ECOG PS 2-3.
b. Patients 70-80 years old with ECOG PS 0-1.
c. Patients 60-70 years old with ECOG PS 2-3.
d. Patients 85 years or older with ECOG PS 1-2.
11. In the current report from the SEARCH database examining statin use and prostate-cancer recurrence in patients after radical prostatectomy, which of the following conclusions can be drawn?
a. Statin use was associated with a dose-dependent decrease in PSA recurrence.
b. Statin use was associated with a dose-dependent decrease in PSA recurrence and improved progression-free survival.
c. Statin use was associated with a dose-dependent decrease in PSA recurrence, progression-free survival, and improved overall survival.
d. None of the above
12. Optimal follow-up of patients found to have monoclonal gammopathy of uncertain significance (MGUS) is associated with which of the following?
a. Identifying multiple myeloma (MM) before symptoms in most patients.
b. Reduced hospitalization and mortality compared to sub-optimal follow-up.
c. A higher percentage of depression compared to sub-optimal follow-up.
d. A higher proportion of diagnosis of smoldering MM compared to sub-optimal follow-up.
Answers: 13. (b); 14. (a); 15. (d)
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.